We studied the effects of a widely-used sulfonylurea, gliclazide, on the oxidizability of lowdensity lipoprotein (LDL) and the development of experimental atherosclerosis in cholesterol-fed rabbits. Daily oral administration of gliclazide (20 mg/kg/day) tended to inhibit the aortic atherosclerosis induced by feeding a 1% cholesterol-diet for 10 weeks, although it did not affect diet-induced hyperlipidemia.
Introduction
Coronary artery disease is the leading cause of death in diabetes mellitus, and diabetes confers a two-to four-fold relative risk of developing coronary artery disease (1) . Even when adjusted for other risk factors such as hypertension and hyperlipidemia, diabetes remains an important cardiovascular risk factor. Diabetes causes a thrombotic tendency in patients, with increased platelet reactivity, impaired fibrinolytic activity, and increased oxidative stress (2) .
It has been shown that hyperglycemia causes the production of free radicals in several ways (3) . This may contribute to the development of diabetic macrovascular complications through increased oxidation of low-density lipoprotein (LDL), which is thought to be a crucial step in the development of atherosclerosis (4, 5) .
Gliclazide, a sulfonylurea in routine clinical use in many countries including Japan, has been shown to have free radical-scavenging activity in vitro and to be an effective inhibitor of in vitro LDL oxidation and more potent on a molar basis than vitamin C (6) . This antioxidant property of gliclazide is not shared by other sulfonylureas such as glibenclamide, tolbutamide and glipizide.
The oxidative modification of LDL is considered to be an important step in the development of atherosclerosis. After initial oxidation of the polyunsaturated fatty acid component of LDL, peroxide products attack the lysine groups of apoprotein B, altering its receptor affinity and allowing uptake by the scavenger receptor on macrophages (4). Therefore, an agent that inhibits LDL oxidation may have the potential to prevent or retard the development of atherosclerosis.
In 1978, Marquie reported that the administration of gliclazide strongly inhibited the development of aortic and particularly coronary lesions induced by the atherogenic diet but did not inhibit the development of plasma lipid disturbances induced by the diet (7). However, he did not study the oxidative stress and did not discuss the antiatherogenic mechanisms of gliclazide.
In the present study, we studied the effects of gliclazide Serum lipids and glucose Serum total cholesterol, HDL-cholesterol and triglyceride levels were similar between the two groups during the study period ( Figs. 2A-C) .
The concentration of TBARS in serum was determined as an indication of lipid peroxidation in vivo. Serum TBARS increased with cholesterol feeding, and was slightly, but not significantly, lower in the gliclazide group than in the control (Fig. 2D ).
The fasting serum glucose level was not different between the two groups (Fig. 3) . After 3 weeks of treatment, blood samples were taken from the 3 rabbits of each group before, 1 hour, 3 hours and 6 hours after receiving the diet in the morning. Slight increases of serum glucose were demonstrated 1 and 3 hours after feeding in the control group without significance . Slight but not significant decrease of serum glucose was demonstrated 1 to 6 hours after feeding in the gliclazide group. Fig. 2 . Changes in serum lipids and TBARS. Serum total cholesterol (A) , HDL-cholesterol (B) and triglyceride (C) levels were similar between the two groups during the study period. Serum TBARS increased with cholesterol feeding, and was slightly, but not significantly lower in the gliclazide group than the control (p=0 .13 at 10 weeks) (D). Changes in blood glucose. Blood samples were taken from 3 rabbits in each group before, 1 hour, 3 hours and 6 hours after given the diet in the morning after 3 weeks and blood glucose was measured. Concentration of gliclazide The concentration of gliclazide in the serum was measured using the HPLC method (Fig. 3) . The concentration of gliclazide in serum increased up to 6 hours after receiving the gliclazide-containing diet in the morning. No gliclazide was detected in serum at the beginning of the experiment in the gliclazide group or in the control group during the study. Gliclazide was not detected in LDL even after receiving the gliclazide-containing diet (data not shown).
LDL oxidizability
The oxidizability of LDL was determined in vitro by continuously measuring the conjugated-diene production induced by incubation with copper. Supplementing the rabbit diet with gliclazide resulted in a 36.7% increase in lag time after 4 weeks of treatment although without significance (Fig. 4) . Prolonged treatment did not lead to a further increase in lag time.
Aortic atherosclerosis
At the end of the study period, the rabbits were killed and their aortas were removed to quantify the extent of atherosclerotic lesion formation. Gliclazide treatment tended to result in a somewhat smaller area covered with atherosclerotic lesions compared with the control, although this was not statistically significant (Fig. 5) .
Other organs
No difference in the weights of heart, liver and kidneys were observed between the gliclazide group and control group (data not shown).
Discussion
Gliclazide is a second generation sulfonylurea that is widely used in the treatment of type II diabetes mellitus and its hypoglycemic activity is well documented (2, 12) . In addition to its metabolic effects, gliclazide has beneficial effects on the hemobiological abnormalities of type II diabetes.
These effects are mediated by the azacyclooctyl ring grafted on to its sulfonylurea core (2) .
Numerous studies have demonstrated that gliclazide reduces platelet hyperadhesion and platelet hyperaggregability (2) . The beneficial effects of the compound on thromboxane/prostacyclin balance have been recently confirmed in type II diabetic patients (13) . Concerning fibrinolysis, gliclazide restores low plasminogen activity to normal in type II diabetic patients previously treated with first-generation sulfonylureas (14) . Gliclazide increases the fibrinolytic potential by increasing endothelial cell tissue plasminogen activator and prekallikrein activity (15) . More recent studies suggest that gliclazide may have effects on the fibrin network structure, rendering the fibrin more amenable to fibrinolysis (16). Diabetes was associated with significant impairment of acetylcholine-induced endothelium-dependent relaxation of the abdominal aorta which was not significant in diabetic rabbits treated with gliclazide in vivo (17). Aortas from diabetic rabbits studied in the presence of a nitric oxide synthase inhibitor, L-NAME showed an exaggerated contraction to acetylcholine which was prevented in rabbits treated with gliclazide.
Furthermore, gliclazide has been shown to have a potent free-radical-scavenging activity in vitro. Glicla- zide scavenges free radicals such as superoxide anion, hydroxyl radical, and nitric oxide in a dose-dependent manner (18, 19). The resistance to oxidation, expressed as the lag time between the addition of copper and commencement of oxidation, was significantly increased by the addtion of gliclazide in vitro (20). LDL isolated from diabetic subjects supplemented with gliclazide had an increased lag time compared with untreated LDL, although other sulfonylureas including glibenclamide, glipizide, and tolbutamide had no effect on lag time. Incubation of human monocytes and bovine endothelial cells with increasing concentrations of gliclazide (2. 
